RE:RE:RE:Seller vs Buyer battleYour posts are always half-baked. I can't tell if it's on purpose or not.
At any rate, the ME problem is absolutely priced in to some degree. The stock has declined for a year by over 50%, so to say otherwise is simply false. Now, if the ME contract didn't go through, I believe the stock would take a hit. I just don't think it would be huge now, and could be recovered within 3-6 months. They've amazingly replaced the ME revenues 100% with outside geographies.
I'm not worried about EPS while in super growth mode. 2019 revenues 100% growth over 2018, and 2020 100% growth over 2019 is what I want to see. If they can break-even or make a little, great. We can worry about EPS in a few years after they've grown their US and European sales.
Covalon has made some good hires lately, with some awesome connections in the medical community.
Get ready for MORE!